Osteoprotegerin diminishes advanced bone cancer pain

Cancer Research

Volumn 61, Issue 10, 2001, Pages 4038-4047

  Luger, Nancy M ^a,c,d   Honore, Prisca ^a,b,d   Sabino, Mary Ann C ^a,b   Schwei, Matthew J ^a,b   Rogers, Scott D ^a,b   Mach, David B ^a,b   Clohisy, Denis R ^b   Mantyh, Patrick W ^a,b  

^a Neurosystems Center and Departments of Preventive Sciences Psychiatry and Neuroscience   (United States)

^b Department of Orthopedic Surgery ^*

^c VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE CANCER; BONE METASTASIS; CANCER PAIN; CELL MATURATION; CONTROLLED STUDY; INFLAMMATORY CELL; INTERNALIZATION; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BLOCKING;

ANIMALS; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; MALE; MICE; MICE, INBRED C3H; NEURONS, AFFERENT; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PAIN; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOMA, EXPERIMENTAL; SPINAL CORD;

EID: 0035872471     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Bone pain
2. Bisphosphonates and breast carcinoma
3. Malignant bone pain: Pathophysiology and treatment
4. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of Phase III trials
5. Diagnosis and monitoring of bone metastases: Clinical means
6. Breakthrough pain: Definition, prevalence and characteristics
7. Breakthrough pain in cancer patients: Pathophysiology and treatment
8. Breakthrough pain: Characteristics and impact in patients with cancer pain
9. The management of cancer pain
10. Pharmacologic management of cancer pain
11. The management of cancer pain
12. Radiotherapy in symptom management
13. Radiotherapy for bone pain
14. Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of life
15. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts
16. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
17. Causes and treatment of bone pain of malignant origin
18. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
19. Therapeutic approaches to bone disease
20. Molecular mechanisms of osteolytic bone metastases
21. Orthopedic management of skeletal metastases
22. 3
23. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation
24. To what extent do spinal interactions between an α-2 adrenoceptor agonist and a μ opioid agonist influence noxiously evoked c-Fos expression in the rat? A pharmacological study
25. Rapid endocytosis of a G protein-coupled receptor: Substance P evoked internalization of its receptor in the rat striatum in vivo
26. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation
27. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states
28. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation
29. Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord-imaging peptide action in vivo
30. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain
31. Transmission of chronic nociception by spinal neurons expressing the substance P receptor
32. The cytoarchitectonic organization of the spinal cord in the rat. I. The lower thoracic and lumbosacral cord
33. Substance P- and CGRP-immunoreactive nerves in bone
34. Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat
35. Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumour necrosis factor α
36. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior
37. Are there long-term changes in the basal or evoked Fos expression in the dorsal horn of the spinal cord of the mononeuropathic rat?
38. cFos and related immediate early gene products as markers of activity in neuroendocrine systems
39. Expression of c-fos protein in brain: Metabolic mapping at the cellular level
40. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: Restoration by MK-801 or dynorphin antiserum
41. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats
42. Bloem and Kroon osseous lesions
43. Radiographic diagnosis and monitoring of bone metastases
44. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
45. Mechanisms and management of bone pain
46. Management of cancer pain
47. Advances in cancer pain
48. Bone resorption by osteoclasts
49. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
50. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
51. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
52. Osteoprogegerin ligand is a cytokine that regulates osteoclast differentiation and activation
53. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
54. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
55. RANK is the intrinsic hematopoietic cell surface receptor that osteoclastogenesis and regulation of bone mass and calcium metabolism
56. T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IGN-γ
57. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
58. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
59. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
60. Skeletal complications of malignancy
61. Therapeutic approaches to bone diseases
62. Anabolic actions of parathyroid hormone on bone
63. PTH: A future role in the management of osteoporosis?
64. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
65. Anabolic effects of parathyroid hormone on bone
66. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
67. Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption
68. An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats
69. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose
70. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones
71. Characterization of cytokine-induced hyperalgesia
72. Contribution of interleukin-1 β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia
73. Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres
74. Hypercalcemia of cancer: An update
75. Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor interleukin-1 α and interleukin-6
76. Osteoid osteoma: The uniquely innervated bone tumor
77. Production of endothelin in human cancer cell lines
78. Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells
79. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
80. Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer
81. Platelet-derived growth factor-AA and α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma
82. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells
83. Neuronal plasticity: Increasing the gain in pain
84. Progressive tactile hypersensitivity: An inflammation-induced incremental increase in the excitability of the spinal cord
85. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor
86. Substance P receptor (neurokinin-1)-expressing neurons in lamina I of the spinal cord encode for the intensity of noxious stimulation: A c-Fos study in rat
87. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons